Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing